Clinical trials: Cancer, Carcinoma
Esophageal Cancer
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
This is a randomized, controlled, multi-center, open trial, unresectable locally advanced or metastatic esophageal squamous cell carcinoma patients that failed at least second-line treatment and overexpressed EGFR were enrolled…
- Trial name
- NCT04415853
- Testing
- Lerotinib, Irinotecan/Tegafur
- Where
- China
- Volunteers
- 416 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Pharmacokinetics, Solid Tumor
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
The purpose of this study is to assess the safety and pharmacokinetics of boserolimab (MK-5890) when administered alone and in combination with pembrolizumab (MK-3475) in adults.
- Conditions
- Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
- Trial name
- NCT03396445
- Testing
- Boserolimab, Pembrolizumab, Pemetrexed
- Where
- 18 sites in United States, Chile and 5 more
- Volunteers
- 182 people
- Sponsor
- Merck Sharp & Dohme LLC
Urothelial Carcinoma (UC)
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma
This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 monotherapy or combined with AK112 in advanced Urothelial carcinoma.
- Trial name
- NCT07636772
- Testing
- AK146D1 for injection, AK112 Injection
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Akeso
Metastatic Head-and-neck Squamous-cell Carcinoma
Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
This phase 2 study is designed to evaluate the safety and activity of TH-4000, a hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.
- Trial name
- NCT02449681
- Testing
- TH-4000 (Tarloxotinib)
- Where
- 10 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- Rain Oncology Inc
Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase
A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)
The aims of the study are to assess the safety profile of brigatinib and the clinical response rates in adults with Anaplastic Lymphoma Kinase (ALK)-Positive Metastatic Non Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT04887519
- Testing
- No Intervention
- Where
- Argentina
- Volunteers
- 39 people
- Sponsor
- Takeda
NSCLC, Non Small Cell Lung Cancer
A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer
For patients diagnosed with early (Stage I) non-small cell lung cancer, a lobe of lung is usually removed at surgery to treat the cancer.
- Trial name
- NCT01237171
- Testing
- Cesium-131 Brachytherapy Seed
- Where
- United States
- Sponsor
- IsoRay Medical, Inc.
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR
- Trial name
- NCT02207530
- Testing
- MEDI4736
- Where
- 108 sites in United States, Belgium and 12 more
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy…
- Trial name
- AEGEAN (NCT03800134)
- Testing
- Durvalumab, Carboplatin, Cisplatin
- Where
- 231 sites in United States, Argentina and 26 more
- Volunteers
- 825 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer, Solid Tumor
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w.
- Trial name
- NCT03080311
- Testing
- APG-1252
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Ascentage Pharma Group Inc.
Carcinoma, Non-Small-Cell Lung
Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy
A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small cell lung cancer patients previously treated with…
- Trial name
- NCT01022671
- Testing
- Belotecan
- Volunteers
- 52 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Non-Small-Cell Lung Cancer
A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer
This study will estimate the response rate in patients with advanced or metastatic non-squamous Non-Small Cell Lung Cancer. Patients who don't progress after 4 to 6 cycles of induction treatment with pemetrexed, cisplatin and…
- Trial name
- NCT00867009
- Testing
- Pemetrexed, Cisplatin, Cetuximab
- Where
- 24 sites in Austria, Germany and 4 more
- Volunteers
- 113 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in participants with metastatic non-small cell lung cancer (NSCLC) in Phase 1…
- Trial name
- swalloWTail (NCT06532032)
- Testing
- Amivantamab, Docetaxel
- Where
- 15 sites in United States, Taiwan and 2 more
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Carcinoma, Non-small Cell Lung Cancer
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy
- Trial name
- CheckMate 79X (NCT04151563)
- Testing
- nivolumab, ipilimumab, cabozantinib
- Where
- 23 sites in United States, Argentina and 8 more
- Sponsor
- Bristol-Myers Squibb
Locally Advanced or Metastatic Epithelial Tumor
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
In phase Ia study, the safety and tolerability of SI-B001 in patients with locally advanced or metastatic epithelial malignancies will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of…
- Trial name
- NCT04603287
- Testing
- SI-B001
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients
Primary: ·To evaluate the activity of the combination of gemcitabine, oxaliplatin and vinorelbine as first line treatment in patients with non-small cell bronchopulmonary cancer Secondary: ·To evaluate the toxicity of the…
- Trial name
- GON (NCT00271271)
- Testing
- oxaliplatine / gemcitabine / Vinorelbine
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Sanofi
Carcinoma, Basal Cell
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
The primary objective is to estimate the objective response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with cemiplimab as a monotherapy
- Trial name
- NCT03132636
- Testing
- cemiplimab
- Where
- 71 sites in United States, Austria and 8 more
- Volunteers
- 138 people
- Sponsor
- Regeneron Pharmaceuticals
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Lung Cancer
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in…
- Trial name
- NCT03322566
- Testing
- Pembrolizumab, Epacadostat, Platinum-based chemotherapy
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 233 people
- Sponsor
- Incyte Corporation
Non-Muscle Invasive Bladder Cancer
Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer
Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy.
- Trial name
- NCT04859751
- Testing
- VB4-845 Injection
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Colorectal Cancer
A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
The primary objective of this study is to compare the activity of raltitrexed and ZD1839 versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by estimating progression free survival (PFS) in…
- Trial name
- NCT00234429
- Testing
- Gefitinib, raltitrexed
- Where
- 9 sites in Spain
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.